CAR19, CARGO, CD19, CD22, CRG-022, Gina Chapman, Third Rock Ventures
Cargo, a cancer drug startup, raises $200 million to combat CAR-T relapse
March 2023: Several types of lymphoma, as well as certain leukaemias and multiple myeloma, can now be effectively treated with CAR-T therapy. Recent studies have demonstrated the efficacy of CAR-T therapy at an earlier stage, res..
axicabtagene ciloleucel, CAR - T Cell therapy, CD19, follicular lymphoma, Kite Pharma, refractory follicular lymphoma, relapsed follicular lymphoma, Yescarta
The FDA has granted axicabtagene ciloleucel expedited approval for relapsed or refractory follicular lymphoma.
August 2021: The FDA has given axicabtagene ciloleucel (Yescarta, Kite Pharma, Inc.) expedited approval for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. A sing..